17-AAG (Tanespimycin)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

17-AAG (Tanespimycin) Chemical Structure

Molecular Weight(MW): 585.69

17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Size Price Stock Quantity  
In DMSO USD 195 In stock
USD 150 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • (A) Cell lines were seeded in 96-well plates and treated with 10 nM of 17-AAG for 72 h. Cell survival was analyzed using CellTiter-Glo. Both parental H3122 cells (red bar) and H3122 CR cells (blue bar) show sensitivity to 17-AAG. (B) Suppression of ALK signaling by 17-AAG in resistant H3122 CR cells. H3122 parental and resistant cells were exposed to increasing concentrations of 17-AAG for 6 h.

    PNAS, 2011, 108: 7535-40. 17-AAG (Tanespimycin) purchased from Selleck.

    Four types of the colon cancer cells with indicated K-Ras phenotype were incubated with indicated concentration of 17-AAG for 24 h, which were then analyzed for protein expression by WB.

    Oncotarget 2014 5, 4269-82. 17-AAG (Tanespimycin) purchased from Selleck.

  • Western blot analysis of immunoprecipitated Hsp90/BIP complexes in MOLT-4 (T-ALL) and RS4;11 (B-ALL) treated for 22 h with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. 500 μg of protein lysates were immunoprecipitated with anti-Hsp90 antibody. Relative Induction values (Rel.Ind.) were obtained by normalizing to Hsp90 bands density. 17-AAG: tanespimycin.

    Oncotarget, 2015, 51: S659-S660. 17-AAG (Tanespimycin) purchased from Selleck.

    UPR modulators destabilize mSmoM2. NIH 3T3 cells expressing mSmoM2 protein were treated with HSP90 inhibitors 17-AAG (50 uM and 100 uM) and SNX-2112 (25 uM and 50 uM) and the proteasome inhibitor bortezomib (25 uM and 50 uM) for 4 h prior to lysis. DMSO was the vehicle control. Western blotting of whole-cell lysates revealed mSmoM2 protein to be destabilized in response to HSP-90 inhibitors but not in response to bortezomib. Tubulin was the loading control. CHOP results indicate ER stress.

    Mol Cell Biol 2013 33(12), 2375-87. 17-AAG (Tanespimycin) purchased from Selleck.

  • Treatment with an Hsp90 inhibitor results in a dose-dependent decrease in complex IV activity. A, because Hsp90 levels were reduced by 80%, in PINK1 null dopaminergic neuronal cells, the effects of specific inhibition of Hsp90 using 17-AAG were analyzed in wild-type neuronal cells. Both complex IV activity and Hsp60 levels were decreased significantly in 17-AAG-treated cells in a dose-dependent manner. B, in contrast, 17-AAG treatment did not affect expression of Hsp90 and LRPPRC.

    J Biol Chem 2012 287, 44109-20. 17-AAG (Tanespimycin) purchased from Selleck.

    SKBR3 cells were treated with FW-04-806 at 10, 20, 40 uM for 24 h; 17AAG was used as a positive control at 1 and 2 uM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using relevant antibodies.

    Mol Cancer 2014 13, 150. 17-AAG (Tanespimycin) purchased from Selleck.

  • Hsp90 is up-regulated during aging. Whole-cell extracts were prepared from young (PD 20) and old (PD 40) HFSN1 cells. c HFSN1 cells (PD 40) were treated with different concentration of the Hsp90 inhibitor (17-AAG) and then re-incubated for 24 h. Whole-cell extracts were prepared and analyzed by western blot using the indicated antibodies.

    Age 2013 35, 549-62. 17-AAG (Tanespimycin) purchased from Selleck.

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description 17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
Features Displays very low toxicity toward normal cells.
Targets
HSP90 [1]
(Cell-free assay)
5 nM
In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. [1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. [2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M{HrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fjbmlEPTB;MD6wNFA{ODNizszN MYLTRW5ITVJ?
IST-MEL1 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMECwOFA4KM7:TR?= MnWxV2FPT0WU
NCI-SNU-1 NVjlUoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TwSGlEPTB;MD6wNFIxPyEQvF2= MXzTRW5ITVJ?
FADU NGTVNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorzTWM2OD1yLkCwNlA6KM7:TR?= MWfTRW5ITVJ?
C32 M{Kzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\CUIxKSzVyPUCuNFA{ODRizszN MXPTRW5ITVJ?
D-566MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTBwMECzPUDPxE1? M1KzZXNCVkeHUh?=
LXF-289 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfBR5FwUUN3ME2wMlAxPDF7IN88US=> NULIPW1rW0GQR1XS
HGC-27 M4Tm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfqelJKSzVyPUCuNFA2OSEQvF2= MoD3V2FPT0WU
RPMI-7951 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PzfWlEPTB;MD6wNFcyPyEQvF2= NV;aWlRYW0GQR1XS
HSC-3 NXzNW3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;vO2lEPTB;MD6wNFkzQSEQvF2= NXTPRZRKW0GQR1XS
MIA-PaCa-2 NVT3dWQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEGwNFkh|ryP M4fMR3NCVkeHUh?=
KS-1 NHq0doxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1cItKSzVyPUCuNFE{PTVizszN NHrCNFZUSU6JRWK=
CAL-51 NET0UZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzib2RKSzVyPUCuNFE1ODVizszN NGf4WXlUSU6JRWK=
MDA-MB-361 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nYOGlEPTB;MD6wNVQ6PSEQvF2= MlnuV2FPT0WU
TI-73 NF7FUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jheGlEPTB;MD6wNVc6PiEQvF2= M1PFNHNCVkeHUh?=
AGS M{\wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnIVnpjUUN3ME2wMlAyQTN6IN88US=> MWPTRW5ITVJ?
NCI-H460 NXGwUFNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjpPINKSzVyPUCuNFE6PzRizszN MU\TRW5ITVJ?
A204 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ToTGlEPTB;MD6wNlI1QSEQvF2= M173RXNCVkeHUh?=
CHL-1 M4XySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP4fpV{UUN3ME2wMlAzOjVzIN88US=> MV;TRW5ITVJ?
DU-4475 NFnzWIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LQbmlEPTB;MD6wNlI3OSEQvF2= NXm2[5hUW0GQR1XS
CGTH-W-1 NXLpVFc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\uTWM2OD1yLkCyN|Q6KM7:TR?= MXzTRW5ITVJ?
HCC2218 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjWeVBKSzVyPUCuNFI1QTRizszN NF35S2ZUSU6JRWK=
A2780 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEK1N|Eh|ryP NVfVbm5tW0GQR1XS
NCI-H720 NGjPXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfkTWM2OD1yLkCyOVQ3KM7:TR?= MYLTRW5ITVJ?
NCI-N87 NHKybpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;0TWM2OD1yLkCyOVk{KM7:TR?= M37FZ3NCVkeHUh?=
CHP-212 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHj6U2hKSzVyPUCuNFI3OjhizszN NYD5NFhXW0GQR1XS
NCI-H23 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr0TWM2OD1yLkCyOlY2KM7:TR?= NIfRcYRUSU6JRWK=
D-263MG MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInWcpRKSzVyPUCuNFI4QDZizszN NHvjT3VUSU6JRWK=
ME-180 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEK4PVEh|ryP MmjIV2FPT0WU
SW982 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjo[I1KSzVyPUCuNFI6QTlizszN NYXoUGMyW0GQR1XS
OE19 M1WxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HCUGlEPTB;MD6wN|A4PyEQvF2= NHLMfGtUSU6JRWK=
SK-LU-1 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEOwPFIh|ryP MXXTRW5ITVJ?
H4 M1XVUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH1bXNKSzVyPUCuNFMxQSEQvF2= Mn[1V2FPT0WU
HT-144 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfyOW1bUUN3ME2wMlA{ODl|IN88US=> NUm0V3BCW0GQR1XS
SK-UT-1 MkPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjpcXdKSzVyPUCuNFMyPzhizszN M2PzTnNCVkeHUh?=
D-336MG NWrRRog3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMEOzNFkh|ryP NIjCeXRUSU6JRWK=
MDA-MB-175-VII NIfIcZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSXlZmUUN3ME2wMlA{OzV2IN88US=> NF\qV2xUSU6JRWK=
GAMG NY\qUGJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjafZR1UUN3ME2wMlA{PDN3IN88US=> M3HWcHNCVkeHUh?=
CP50-MEL-B MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3fWlEPTB;MD6wN|Q2KM7:TR?= Mn\xV2FPT0WU
OVCAR-5 NHK0ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ofoJRUUN3ME2wMlA{PDhizszN Mn;OV2FPT0WU
SK-MES-1 MmfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XPVGlEPTB;MD6wN|YxPiEQvF2= Mo\vV2FPT0WU
VM-CUB-1 M2CyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfrVHVKSzVyPUCuNFM3PTdizszN NWjLW2NiW0GQR1XS
WM-115 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTOTWM2OD1yLkCzO|YzKM7:TR?= NVLlNnc1W0GQR1XS
DSH1 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEO4NFch|ryP Ml7uV2FPT0WU
Becker M2fEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjIWo1iUUN3ME2wMlA{QDh3IN88US=> MorJV2FPT0WU
SW962 NFKxOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3SOWg6UUN3ME2wMlA{QTR3IN88US=> NV\ITpFzW0GQR1XS
TYK-nu M2S1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEO5PFUh|ryP M1vCRnNCVkeHUh?=
HO-1-N-1 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX65WHlPUUN3ME2wMlA1ODJzIN88US=> MYrTRW5ITVJ?
T98G MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7RTWM2OD1yLkC0NVA{KM7:TR?= M{PSdHNCVkeHUh?=
ACN NHnDUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXTUJlKSzVyPUCuNFQyPjJizszN M3HtRnNCVkeHUh?=
SW780 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NImxPJFKSzVyPUCuNFQzODNizszN MmDNV2FPT0WU
Detroit562 MmjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\RWXhKSzVyPUCuNFQzOzlizszN NWPLenF2W0GQR1XS
BB49-HNC NWOyb2hPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3RU21ZUUN3ME2wMlA1OjR|IN88US=> MYLTRW5ITVJ?
HN NHzhZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjFTWM2OD1yLkC0NlczKM7:TR?= MUDTRW5ITVJ?
H9 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DpcmlEPTB;MD6wOFM4OSEQvF2= MmP3V2FPT0WU
VA-ES-BJ MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHsbZVKSzVyPUCuNFQ1PDdizszN M361SXNCVkeHUh?=
MEL-JUSO NUPMPJRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfoN|Z7UUN3ME2wMlA1PDd3IN88US=> MnHwV2FPT0WU
BT-474 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITqSZBKSzVyPUCuNFQ2KM7:TR?= M3zad3NCVkeHUh?=
CaR-1 NXvCOZJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHBTWM2OD1yLkC0OVQ6KM7:TR?= NVnmXItrW0GQR1XS
PSN1 MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSzTWM2OD1yLkC0OlA{KM7:TR?= MW\TRW5ITVJ?
KYSE-510 MoTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nUVWlEPTB;MD6wOFY1QSEQvF2= MUPTRW5ITVJ?
KP-4 NE\DeXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m1NmlEPTB;MD6wOFc2OyEQvF2= NUXNdpdpW0GQR1XS
KYSE-410 NFHpSoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMES3O|Ih|ryP MYrTRW5ITVJ?
G-402 NH7DXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvSZXpKSzVyPUCuNFQ4QDlizszN NUL3[nFkW0GQR1XS
DOK M173WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDJdWRKSzVyPUCuNFQ6ODJizszN MX\TRW5ITVJ?
COR-L88 M32wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXwTWM2OD1yLkC0PVEzKM7:TR?= M{TUTnNCVkeHUh?=
SKG-IIIa MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\nO2lEPTB;MD6wOFk5PiEQvF2= MnnrV2FPT0WU
AN3-CA Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXoSJlSUUN3ME2wMlA2KM7:TR?= MUTTRW5ITVJ?
SW48 NHPuNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\aTWM2OD1yLkC1NFM6KM7:TR?= M2PSUnNCVkeHUh?=
YKG-1 Ml;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml25TWM2OD1yLkC1NFcyKM7:TR?= MV\TRW5ITVJ?
KYSE-150 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETEOFZKSzVyPUCuNFUzOzVizszN MnLoV2FPT0WU
HuO-3N1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMEWyN|ch|ryP NFT3OZpUSU6JRWK=
LB1047-RCC NHnlUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TSU2lEPTB;MD6wOVI6PiEQvF2= M4DvR3NCVkeHUh?=
NCI-H2030 NFn0fZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEW0NVQh|ryP M2HyZnNCVkeHUh?=
YH-13 M2DSOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEW3NlIh|ryP MUTTRW5ITVJ?
5637 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEW3OEDPxE1? M1;uTXNCVkeHUh?=
LOXIMVI Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITEd2FKSzVyPUCuNFU5PzJizszN NVra[pFzW0GQR1XS
GT3TKB MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPjNnNKSzVyPUCuNFU6PDJizszN NX33VGxxW0GQR1XS
TCCSUP NEj1SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTS[2RSUUN3ME2wMlA2QTZ2IN88US=> MX;TRW5ITVJ?
EPLC-272H M4HJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq2WG0{UUN3ME2wMlA3OjB3IN88US=> MnLzV2FPT0WU
LU-99A NEnwXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPKXWRlUUN3ME2wMlA3OjN5IN88US=> NV;Od4dCW0GQR1XS
NCI-H1755 NFXTeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i4N2lEPTB;MD6wOlM1OSEQvF2= MVPTRW5ITVJ?
KM12 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwME[zOFgh|ryP NUXudIRJW0GQR1XS
SF295 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nVSmlEPTB;MD6wOlQ2OiEQvF2= MUfTRW5ITVJ?
MZ2-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7rTWM2OD1yLkC2OVU{KM7:TR?= MV;TRW5ITVJ?
HEC-1 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrMdFc3UUN3ME2wMlA3PTh6IN88US=> MmToV2FPT0WU
SW684 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zvWWlEPTB;MD6wOlU6OSEQvF2= NWjsXpdkW0GQR1XS
SF539 MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwME[2PFEh|ryP MV3TRW5ITVJ?
GMS-10 NWfGXG9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXn3U5hLUUN3ME2wMlA3Pjl7IN88US=> M1LsfXNCVkeHUh?=
MV-4-11 NHW5W5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33TTGlEPTB;MD6wOlgxOyEQvF2= NYLkS2p1W0GQR1XS
HT-29 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTWVHEyUUN3ME2wMlA3QTF7IN88US=> NEK4TVVUSU6JRWK=
23132-87 M2TnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDKTWM2OD1yLkC2PVUh|ryP M3PqenNCVkeHUh?=
SW620 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfDTWM2OD1yLkC3NFI3KM7:TR?= MoTBV2FPT0WU
HCC1806 MojSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjCc2tYUUN3ME2wMlA4OTNzIN88US=> M3nhNHNCVkeHUh?=
Hs-578-T NXHRcWlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHhTWM2OD1yLkC3NlA5KM7:TR?= MWLTRW5ITVJ?
A2058 NF7KTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWweJZlUUN3ME2wMlA4OjJ6IN88US=> MkL4V2FPT0WU
MEL-HO M1vSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfPWZFKSzVyPUCuNFczPTVizszN M{DpN3NCVkeHUh?=
HCC2998 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nJbGlEPTB;MD6wO|M1PyEQvF2= NFLhcVBUSU6JRWK=
HuO9 NUTuVYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWb4xKSzVyPUCuNFc2QDlizszN MkLaV2FPT0WU
CAL-39 M2T3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfFemNoUUN3ME2wMlA4PzZ4IN88US=> Mo\yV2FPT0WU
M14 M2OwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMEe5NVMh|ryP MoK4V2FPT0WU
BFTC-909 M2j4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DjWGlEPTB;MD6wO|k3QSEQvF2= NHTTTHhUSU6JRWK=
TE-11 M3z5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMEe5PVYh|ryP MXPTRW5ITVJ?
TGBC1TKB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XUW2lEPTB;MD6wPFA1OyEQvF2= Mn;5V2FPT0WU
L-363 M1fSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W0fWlEPTB;MD6wPFIxPiEQvF2= MmHnV2FPT0WU
A431 M{noT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtTmpKSzVyPUCuNFgzOSEQvF2= MXfTRW5ITVJ?
MKN45 NHHF[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfRW5lKSzVyPUCuNFgzOTlizszN NG[xV3FUSU6JRWK=
HT-1080 NHLr[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDVWnhKSzVyPUCuNFg1OzlizszN M4jZRnNCVkeHUh?=
OVCAR-8 M1\PZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDqeXlUUUN3ME2wMlA5PjJ{IN88US=> MlWyV2FPT0WU
LCLC-97TM1 Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITZV|dKSzVyPUCuNFg4OjhizszN NXm3N4hDW0GQR1XS
M059J NFjHOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEmwNlch|ryP M4e1OnNCVkeHUh?=
SK-MEL-2 NGjVR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMEmwOkDPxE1? MoXKV2FPT0WU
TE-1 NIftbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjzTnZKSzVyPUCuNFkzODRizszN MXjTRW5ITVJ?
KYSE-180 NHvLbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf0bI1LUUN3ME2wMlA6OjZ{IN88US=> MnLHV2FPT0WU
D-247MG M{e4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMEm0OVUh|ryP NIK4OXZUSU6JRWK=
8-MG-BA NYnHSHNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEm0O|Ih|ryP M3jE[XNCVkeHUh?=
NCI-H1792 M2TrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KxXWlEPTB;MD6wPVYyQCEQvF2= M4C5VnNCVkeHUh?=
MCF7 NHq5PIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HqTmlEPTB;MD6wPVY4PyEQvF2= MUTTRW5ITVJ?
NCI-H2122 MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rvRWlEPTB;MD6wPVc1PSEQvF2= Ml:1V2FPT0WU
EFO-27 NEPNSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Pl[2lEPTB;MD6wPVk6PyEQvF2= NHjY[ldUSU6JRWK=
LB2241-RCC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW3eIdmUUN3ME2wMlExODV2IN88US=> NWPaPVU6W0GQR1XS
SN12C M1rKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDON3lKSzVyPUCuNVAyODdizszN MX;TRW5ITVJ?
A498 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUCxPEDPxE1? MU\TRW5ITVJ?
PANC-03-27 NWLw[lRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\hTWlEPTB;MD6xNFI5PiEQvF2= MmPJV2FPT0WU
NCI-H1581 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG1TWM2OD1yLkGwNlkh|ryP NYjWUHdCW0GQR1XS
U-87-MG NF7oblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PEZ2lEPTB;MD6xNFMxPyEQvF2= MkH1V2FPT0WU
G-401 NXK2UWkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3zTWM2OD1yLkGwN|U{KM7:TR?= MnTHV2FPT0WU
SiHa MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GzOGlEPTB;MD6xNFQ5PiEQvF2= M2jPZnNCVkeHUh?=
U251 NVfLU2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;pSmlEPTB;MD6xNFUzPSEQvF2= NEnZfmdUSU6JRWK=
MMAC-SF NXXX[ZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMUC1N|Eh|ryP M4myb3NCVkeHUh?=
BB65-RCC NYWwV4NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjyXmU2UUN3ME2wMlExPTV2IN88US=> NH;JPGpUSU6JRWK=
NKM-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3XTWM2OD1yLkGwOlY3KM7:TR?= NWP6WWF4W0GQR1XS
HD-MY-Z M1fmWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzUVYRKSzVyPUCuNVA5PzNizszN NVjHV3p1W0GQR1XS
TGBC11TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTXXZBKSzVyPUCuNVA6ODNizszN NX;tSY5yW0GQR1XS
COLO-679 NE\4epdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHETWM2OD1yLkGxNlEyKM7:TR?= NXvRO4tLW0GQR1XS
TE-8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPueVFKSzVyPUCuNVEzPjRizszN NUPuXnV[W0GQR1XS
SK-MEL-28 NHLES5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XMeGlEPTB;MD6xNVMzOSEQvF2= MVrTRW5ITVJ?
SH-4 NXraNWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUGzOVYh|ryP NX7YO2dXW0GQR1XS
KALS-1 NV3rSpo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHmTWM2OD1yLkGxN|k{KM7:TR?= MoTSV2FPT0WU
RKO MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;2eGlEPTB;MD6xNVc3PCEQvF2= NWjMbY12W0GQR1XS
OMC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS1TZgyUUN3ME2wMlEyPzl5IN88US=> MniwV2FPT0WU
BT-549 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTIVZpmUUN3ME2wMlEyPzl7IN88US=> M2[2fXNCVkeHUh?=
NCI-H28 MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPze49vUUN3ME2wMlEyQDF5IN88US=> M2DIXHNCVkeHUh?=
RXF393 NWXNd4RYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1O1RmlEPTB;MD6xNVk5OiEQvF2= MVHTRW5ITVJ?
COLO-829 NXS4dpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Ke2lEPTB;MD6xNlAxPSEQvF2= NX7KW4lJW0GQR1XS
HMV-II M1zROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTOSHhSUUN3ME2wMlEzODJizszN M{XaPXNCVkeHUh?=
SW1990 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMUKxOVch|ryP M1jVd3NCVkeHUh?=
NCI-H1437 NVTJ[ZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonZTWM2OD1yLkGyNVU4KM7:TR?= M3HrU3NCVkeHUh?=
SNB75 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPjUW5XUUN3ME2wMlEzOTZ7IN88US=> MmXHV2FPT0WU
EW-3 NUH3NnJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq2foxxUUN3ME2wMlEzPjZzIN88US=> M1zo[HNCVkeHUh?=
SAS Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPNTWM2OD1yLkGyOlkh|ryP MnHZV2FPT0WU
NCI-H1666 M2rDUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntRZNYUUN3ME2wMlEzPzd2IN88US=> M{XOXHNCVkeHUh?=
A375 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUK3O|gh|ryP NHrtN4lUSU6JRWK=
CAMA-1 NXvqcFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDDTWM2OD1yLkGyPVI1KM7:TR?= MXHTRW5ITVJ?
HuP-T4 M1nMOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYizU4d3UUN3ME2wMlEzQTR|IN88US=> NULyTpk2W0GQR1XS
NCI-H292 NEPEbWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUOxNUDPxE1? M4nTbHNCVkeHUh?=
PC-14 M3;6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPDTWM2OD1yLkGzNlEyKM7:TR?= M3XCWXNCVkeHUh?=
BPH-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMUO0NUDPxE1? NFLaO4FUSU6JRWK=
GAK NUTjfW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2iwNWlEPTB;MD6xN|U3PyEQvF2= M4PKZXNCVkeHUh?=
VMRC-RCZ NGPtNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3LTWM2OD1yLkGzO|YzKM7:TR?= MWHTRW5ITVJ?
SK-MEL-24 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17QXmlEPTB;MD6xN|g4KM7:TR?= MkPBV2FPT0WU
LB831-BLC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrGUnd5UUN3ME2wMlE{QDh|IN88US=> NUTobXRWW0GQR1XS
NCI-H2452 NIeyVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMUO5OVYh|ryP NGTCVlBUSU6JRWK=
RT-112 NI\MUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\6TlNKSzVyPUCuNVQxOzVizszN NWf6VXF7W0GQR1XS
GP5d M2mzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vKVmlEPTB;MD6xOFExPCEQvF2= NGX4U4xUSU6JRWK=
LC-2-ad M{nxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe2SJpKSzVyPUCuNVQyOjFizszN NYnQXIVYW0GQR1XS
MPP-89 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7hWlBKSzVyPUCuNVQyOjVizszN NFT1WVVUSU6JRWK=
NUGC-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXVTWM2OD1yLkG0OFc5KM7:TR?= Mn7MV2FPT0WU
GI-1 M4nxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4juXmlEPTB;MD6xOFU2QCEQvF2= MWnTRW5ITVJ?
HCC1419 M1S0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M360b2lEPTB;MD6xOFU4PiEQvF2= NF7QTJBUSU6JRWK=
SW1573 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUS3OVgh|ryP M13PUXNCVkeHUh?=
NCI-H2347 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUS4N|kh|ryP NWj3d4V6W0GQR1XS
Mewo Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMUS4PFkh|ryP M2OwO3NCVkeHUh?=
639-V MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOxSGRKSzVyPUCuNVUxOTNizszN NYXsZlZlW0GQR1XS
AsPC-1 NHWxe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG1bVJLUUN3ME2wMlE2OjJ3IN88US=> MXPTRW5ITVJ?
NCI-H1648 NELub2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnCXGFKSzVyPUCuNVUzOzJizszN M33xTXNCVkeHUh?=
786-0 NIHNUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrITWM2OD1yLkG1N|gyKM7:TR?= NV3mb3Z5W0GQR1XS
ETK-1 M3nobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjSNXU5UUN3ME2wMlE2QSEQvF2= M17mSnNCVkeHUh?=
BxPC-3 M1XwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;Bc2VKSzVyPUCuNVU6PjZizszN M4GzcXNCVkeHUh?=
CAL-62 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHiy[4NKSzVyPUCuNVYyPjlizszN MnnCV2FPT0WU
HCC1937 NH7HTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[5dYFnUUN3ME2wMlE3Ojd3IN88US=> NHHGSo9USU6JRWK=
NCI-H1299 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHSW5YzUUN3ME2wMlE3Ojh3IN88US=> M2DubHNCVkeHUh?=
SW1088 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrablA{UUN3ME2wMlE3PDF|IN88US=> MnvuV2FPT0WU
FTC-133 M3X6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMU[1OEDPxE1? MnqwV2FPT0WU
OC-314 M4jRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjKb2RKSzVyPUCuNVY3QSEQvF2= MXTTRW5ITVJ?
SCC-9 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMU[3NVYh|ryP NHjMVnFUSU6JRWK=
HT-1376 NIX2clBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMU[5N|Yh|ryP NIC2UmlUSU6JRWK=
U-2-OS NYTyfnNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLKTWM2OD1yLkG3NVc{KM7:TR?= MXvTRW5ITVJ?
COLO-824 NH3FbHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13PXmlEPTB;MD6xO|I6PCEQvF2= MXnTRW5ITVJ?
BB30-HNC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInHWJJKSzVyPUCuNVc{OyEQvF2= MkHMV2FPT0WU
NCI-H2087 MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv0[olKSzVyPUCuNVc{PjhizszN MXfTRW5ITVJ?
NCI-H2170 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHIVItKSzVyPUCuNVc2OzZizszN NIfqUINUSU6JRWK=
SK-OV-3 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjacWpIUUN3ME2wMlE4PTdzIN88US=> MlSyV2FPT0WU
MZ7-mel MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrzTWM2OD1yLkG3OlQ6KM7:TR?= MnjxV2FPT0WU
NCI-H650 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO3TWM2OD1yLkG3OlgzKM7:TR?= NEe3fYtUSU6JRWK=
KOSC-2 MojjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMUe3N|Qh|ryP MonqV2FPT0WU
SCC-4 Mn;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r3XWlEPTB;MD6xO|c4PyEQvF2= MWTTRW5ITVJ?
MDA-MB-157 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIeyXm1KSzVyPUCuNVgxQDJizszN MU\TRW5ITVJ?
KYSE-520 MomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMUiyJO69VQ>? MX7TRW5ITVJ?
LK-2 M2DtbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi5cndKSzVyPUCuNVg{ODNizszN M3TVe3NCVkeHUh?=
KNS-81-FD NYL2TnM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LjdmlEPTB;MD6xPFM6PCEQvF2= NEDHd|ZUSU6JRWK=
IGROV-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nVfGlEPTB;MD6xPFQ1OyEQvF2= MoL3V2FPT0WU
DEL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUi0OUDPxE1? NVvFS2h7W0GQR1XS
NCI-H1395 NFP6cnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz3TWM2OD1yLkG4OlgzKM7:TR?= NXT2Z2JMW0GQR1XS
JEG-3 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH1[opKSzVyPUCuNVg4ODVizszN NYfzUoZUW0GQR1XS
BCPAP MlzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwMUi4O|Ih|ryP MVzTRW5ITVJ?
CAL-27 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P3WWlEPTB;MD6xPVAzOiEQvF2= NIrwVnRUSU6JRWK=
RD NHvMR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jNZmlEPTB;MD6xPVEyOyEQvF2= MXnTRW5ITVJ?
RVH-421 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C2bWlEPTB;MD6xPVEyPiEQvF2= NV76OZNJW0GQR1XS
Capan-2 M1rr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3exbmlEPTB;MD6xPVI2PiEQvF2= NEHvS|JUSU6JRWK=
COLO-680N NYLMPIhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwMUmzOlQh|ryP NEfTZXJUSU6JRWK=
NCI-H1650 NX;UOoRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwMkCwOVch|ryP Mlv1V2FPT0WU
SBC-5 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorGTWM2OD1yLkKwNVE5KM7:TR?= NVq3SGFSW0GQR1XS
U031 NYP1dGE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LxeWlEPTB;MD6yNFU1PyEQvF2= M3LlNnNCVkeHUh?=
S-117 Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrMT2NbUUN3ME2wMlIxPTZ2IN88US=> NWPmRpppW0GQR1XS
DoTc2-4510 NWK1VnV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMkC3Olkh|ryP NF3PR4pUSU6JRWK=
AM-38 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDhZmhKSzVyPUCuNlA5PDhizszN NIjvOJdUSU6JRWK=
A172 NFPMSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDzSVhKSzVyPUCuNlExOjJizszN NGTSUG1USU6JRWK=
HPAF-II NVHZcG9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPGTWM2OD1yLkKxNlY1KM7:TR?= NVW0fXdPW0GQR1XS
769-P MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nwRWlEPTB;MD6yNVI5KM7:TR?= MVvTRW5ITVJ?
MFE-280 NHHvcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXTTWM2OD1yLkKxNlk5KM7:TR?= M{XzT3NCVkeHUh?=
TE-9 NUf5c2dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjzbWtKSzVyPUCuNlE4QDZizszN MYDTRW5ITVJ?
C2BBe1 NVzRWlZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;IPWVZUUN3ME2wMlIzOTlizszN M3;lTXNCVkeHUh?=
EoL-1-cell NGTvOYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nvWGlEPTB;MD6yNlIxOyEQvF2= MnvnV2FPT0WU
G-361 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDtVWJKSzVyPUCuNlI3QDJizszN M2DST3NCVkeHUh?=
KYSE-270 NVe0W25rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMkOwPFQh|ryP NWjBcoxCW0GQR1XS
TK10 NF3ncGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMkOxNVch|ryP MWHTRW5ITVJ?
ML-2 NH\1cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGj1SHFKSzVyPUCuNlMyOTlizszN NW\C[YcxW0GQR1XS
MHH-ES-1 Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLtTWM2OD1yLkKzOlgyKM7:TR?= M4DZdHNCVkeHUh?=
BHY M4nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDKTFJTUUN3ME2wMlI{PjlzIN88US=> Mmj2V2FPT0WU
LS-513 M{XZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkftTWM2OD1yLkKzPVYyKM7:TR?= NVLFNpJoW0GQR1XS
COLO-678 NX\VboRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\zT2lEPTB;MD6yOFA1PCEQvF2= MWHTRW5ITVJ?
NCI-H747 MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMkSxOlkh|ryP MlT4V2FPT0WU
K5 NVjtfHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzaWJBSUUN3ME2wMlI1OzhizszN NXPWO2k6W0GQR1XS
OS-RC-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTnVYhKSzVyPUCuNlQ2ODlizszN MYHTRW5ITVJ?
KINGS-1 NY\PeYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfzTWM2OD1yLkK0OVI6KM7:TR?= MVPTRW5ITVJ?
SCC-25 NGDX[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMkS1OlMh|ryP NGTlXGlUSU6JRWK=
CAPAN-1 MlO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL1TWM2OD1yLkK0O|g{KM7:TR?= MYnTRW5ITVJ?
ESS-1 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTBwMkS4NFUh|ryP NVLOW|IxW0GQR1XS
TE-6 NVrNO4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ezSmlEPTB;MD6yOVc2KM7:TR?= MljFV2FPT0WU
LB2518-MEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX35SGFqUUN3ME2wMlI2Pzd5IN88US=> NG[0ZnNUSU6JRWK=
COLO-800 NGC5UYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPCTY9iUUN3ME2wMlI2QDF{IN88US=> MXHTRW5ITVJ?
LU-134-A M2HHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF20ZVdKSzVyPUCuNlYyOzZizszN NUC0R3E1W0GQR1XS
NCI-H1155 NIXwRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXvTWM2OD1yLkK2NVYzKM7:TR?= MWfTRW5ITVJ?
MFM-223 NXziNnF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37WNGlEPTB;MD6yOlM3OyEQvF2= NETsOZRUSU6JRWK=
HTC-C3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\4ZWlEPTB;MD6yOlUxPiEQvF2= NXS2bnJWW0GQR1XS
HCT-116 M3;jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzQTWM2OD1yLkK2OVk6KM7:TR?= MXLTRW5ITVJ?
Ca-Ski Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zufmlEPTB;MD6yOlY4QCEQvF2= NXzCSWkxW0GQR1XS
SBC-1 NV7LSG57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrepg4UUN3ME2wMlI3PzR{IN88US=> M1n6[XNCVkeHUh?=
NB69 M4DqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXPUllbUUN3ME2wMlI4ODh5IN88US=> MoS4V2FPT0WU
J82 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fCUWlEPTB;MD6yO|I3PSEQvF2= Mo\ZV2FPT0WU
U-118-MG NHTLXYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTBwMke1O|kh|ryP NUXESHQ2W0GQR1XS
NCI-H1355 M{D0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;n[FFKSzVyPUCuNlgxPzRizszN NYTjPFZJW0GQR1XS
NCI-H1048 NFLzN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjqepN5UUN3ME2wMlI5QTV4IN88US=> M3HlNXNCVkeHUh?=
SW954 Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnqTWM2OD1yLkK5NlI4KM7:TR?= Mlf0V2FPT0WU
NMC-G1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zBV2lEPTB;MD6yPVI4PyEQvF2= M3y3bHNCVkeHUh?=
SW1710 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMkm0PVQh|ryP MVLTRW5ITVJ?
KY821 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlewTWM2OD1yLkK5PFczKM7:TR?= M1WyUHNCVkeHUh?=
HCC38 NYfuRmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTB[5VKSzVyPUCuN|AxPzhizszN M4XjWHNCVkeHUh?=
NCI-SNU-5 Mn;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XJVmlEPTB;MD6zNFU1KM7:TR?= NIj2dWNUSU6JRWK=
ES8 NFHPcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zwNmlEPTB;MD6zNFc5PCEQvF2= MWrTRW5ITVJ?
COLO-792 NVfJ[3JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjGZoE1UUN3ME2wMlMyOjVzIN88US=> M2HNZ3NCVkeHUh?=
BFTC-905 NIHjWYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYntVZRQUUN3ME2wMlMyPTJzIN88US=> MoLUV2FPT0WU
ChaGo-K-1 M3vzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwM{G3NVUh|ryP MYnTRW5ITVJ?
Daoy NXTCZ4pXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwM{G3NlMh|ryP MlfuV2FPT0WU
SJSA-1 NWSye3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmzcm1KSzVyPUCuN|E5PDdizszN MWLTRW5ITVJ?
KNS-62 NG\VToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TIdWlEPTB;MD6zNlA5QCEQvF2= MV7TRW5ITVJ?
CAKI-1 M1PDS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwM{KxNVEh|ryP NH:2WWFUSU6JRWK=
UACC-62 NFrJZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m2cWlEPTB;MD6zNlIzPyEQvF2= MUXTRW5ITVJ?
HuCCT1 M3rCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwM{KyPFMh|ryP MVTTRW5ITVJ?
CTB-1 M4S4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{K3OVMh|ryP NFPCPWVUSU6JRWK=
NTERA-S-cl-D1 M13CN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLTTI1KSzVyPUCuN|I5OzZizszN M{XNOXNCVkeHUh?=
T-24 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zbIxKSzVyPUCuN|MyPTlizszN M{jJdnNCVkeHUh?=
KYSE-70 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTwTWM2OD1yLkOzNlg{KM7:TR?= NWnqVJViW0GQR1XS
SW626 M3vNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;tPYZKSzVyPUCuN|M2OzJizszN NWruU3BTW0GQR1XS
LB996-RCC NF;mfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwM{O2NVkh|ryP NFvYSFlUSU6JRWK=
DMS-273 NGfNflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGxfZBKSzVyPUCuN|M6OTZizszN M1m0RnNCVkeHUh?=
SW1783 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;uXGlEPTB;MD6zN|k6PyEQvF2= NETjUmlUSU6JRWK=
KU812 NXvEOIRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTBwM{SwN|gh|ryP NFjYOZpUSU6JRWK=
HSC-2 NXPIcWdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTBwM{SwOVMh|ryP MnnHV2FPT0WU
A3-KAW NIL5UJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwM{SxOlIh|ryP MkexV2FPT0WU
COLO-684 NHG3emFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\EZ5ZKSzVyPUCuN|Q2ODFizszN Mmj0V2FPT0WU
NCI-H2405 NELCTVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jUcGlEPTB;MD6zOFY{OSEQvF2= MWXTRW5ITVJ?
NCI-H2228 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPBdXFKSzVyPUCuN|U{PTdizszN NYS2TZMzW0GQR1XS
NB13 M3vyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L2d2lEPTB;MD6zOlgzQSEQvF2= NV\hS29yW0GQR1XS
no-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO4TYZXUUN3ME2wMlM3QTVizszN MUTTRW5ITVJ?
DK-MG NETDNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwM{exPFgh|ryP M{H5[3NCVkeHUh?=
NBsusSR M{f1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzZR45KSzVyPUCuN|czQDVizszN M2LjVHNCVkeHUh?=
KP-N-YS M3ryS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojETWM2OD1yLkO3OFY{KM7:TR?= NGHnXnNUSU6JRWK=
CFPAC-1 NUHlSmRLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXFTWM2OD1yLkO3OVE5KM7:TR?= MoDjV2FPT0WU
KARPAS-45 M3rw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjmN2V3UUN3ME2wMlM4QDZ{IN88US=> NV\GNVNsW0GQR1XS
NCI-H1793 M{jZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwM{i1NUDPxE1? MUDTRW5ITVJ?
HCE-T NWO0RXhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Twe2lEPTB;MD6zPFYxOyEQvF2= MWPTRW5ITVJ?
NCI-H520 NXO4cJBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHDTWM2OD1yLkO4O|A{KM7:TR?= NXTKPY1ZW0GQR1XS
HCC2157 NFTwXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwM{i3PFEh|ryP NV3tfHFZW0GQR1XS
EW-18 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\xR2lEPTB;MD6zPFk1OSEQvF2= NYHYRXptW0GQR1XS
RO82-W-1 NVzKSItqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmOwTWM2OD1yLkO5Olk6KM7:TR?= NVnRZWRYW0GQR1XS
HuP-T3 NYjaVVRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjoTWM2OD1yLkSwNVQ{KM7:TR?= NFzDfFBUSU6JRWK=
PANC-10-05 NYjSSFNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnIXm1KSzVyPUCuOFEyPyEQvF2= MWjTRW5ITVJ?
NCI-H1703 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTPOIRUUUN3ME2wMlQyPDR4IN88US=> NEPzTG9USU6JRWK=
TE-10 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\kNmlEPTB;MD60NVQ1PyEQvF2= M2q0NnNCVkeHUh?=
HOS NV35UFg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNEG2PFIh|ryP M4q5RnNCVkeHUh?=
LN-405 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vQcGlEPTB;MD60NVY5PyEQvF2= NUSx[IxUW0GQR1XS
A427 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;pTWM2OD1yLkSxPVgyKM7:TR?= NUm5eW56W0GQR1XS
CAL-12T M3Xmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH2yZW9KSzVyPUCuOFI4QCEQvF2= MYjTRW5ITVJ?
SW756 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3XTWM2OD1yLkS0NVg{KM7:TR?= MUnTRW5ITVJ?
YAPC NXHnWIZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwNEWwPEDPxE1? M{XEfHNCVkeHUh?=
GOTO MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwNEWxOkDPxE1? M1zKN3NCVkeHUh?=
C3A NIH5NIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNEW0N|ch|ryP MYHTRW5ITVJ?
UM-UC-3 MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn5NFBKSzVyPUCuOFU1PyEQvF2= NV63SWNoW0GQR1XS
NCI-H1573 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX0TWM2OD1yLkS1OVY6KM7:TR?= NVLlNYFDW0GQR1XS
LS-411N MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTaTWM2OD1yLkS2OVI4KM7:TR?= Mn\NV2FPT0WU
COR-L23 NXHGSI11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDJTWM2OD1yLkS2O|Y1KM7:TR?= NHy4flBUSU6JRWK=
HCE-4 MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwNEe0OFYh|ryP MYTTRW5ITVJ?
NCI-H2291 NHT2UVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjseotKSzVyPUCuOFc5QTZizszN MoS3V2FPT0WU
A101D NHv1OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLnTWM2OD1yLkS4NFU{KM7:TR?= MnnQV2FPT0WU
HT-3 NYrTOXc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7YNHJbUUN3ME2wMlQ5OjF5IN88US=> MXjTRW5ITVJ?
HOP-62 NEjm[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwNEm4OlUh|ryP M3;NbnNCVkeHUh?=
PC-3 NHO2bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1:xOmlEPTB;MD61NVUxPyEQvF2= M{jsPHNCVkeHUh?=
CTV-1 NF3KPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jKZ2lEPTB;MD61NlY3QSEQvF2= MWTTRW5ITVJ?
PANC-08-13 Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K5U2lEPTB;MD61N|E4PyEQvF2= NF64S41USU6JRWK=
CAL-120 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjyNolwUUN3ME2wMlU{Ozl7IN88US=> M{HROHNCVkeHUh?=
UMC-11 NYrLNJg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNUWyN|Qh|ryP MUHTRW5ITVJ?
MSTO-211H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD3Wlg3UUN3ME2wMlU2PzZ{IN88US=> MVTTRW5ITVJ?
NCI-H2126 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XtZ2lEPTB;MD61OlgyPSEQvF2= MmHVV2FPT0WU
SNU-C2B MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHvOJpKSzVyPUCuOVc6PzdizszN MUTTRW5ITVJ?
DBTRG-05MG NV30VmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwNUiwOVMh|ryP NEnwXZJUSU6JRWK=
MKN1 NUW2d442T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfYbFZKSzVyPUCuOVg4QDNizszN MWjTRW5ITVJ?
ES3 NVTONJVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVe1V|N5UUN3ME2wMlU6OTJ2IN88US=> MnfyV2FPT0WU
OVCAR-3 M4XMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwNUmzOFEh|ryP MVLTRW5ITVJ?
ACHN NG\aR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vte2lEPTB;MD62NFU3QSEQvF2= MWXTRW5ITVJ?
SW872 NYPlWFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3WwXmlEPTB;MD62NFc3OyEQvF2= NYOyO4pWW0GQR1XS
CP66-MEL NEnEelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS1TWM2OD1yLk[wPVY6KM7:TR?= MVrTRW5ITVJ?
NCI-H661 NWj1c|FnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwNkGxNFQh|ryP M37vPHNCVkeHUh?=
UACC-893 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLPXHRKSzVyPUCuOlM3QDFizszN M3ruVXNCVkeHUh?=
JVM-3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\wTWM2OD1yLk[zPFA1KM7:TR?= MoHmV2FPT0WU
SF268 M2XmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfzZ5JKSzVyPUCuOlQ{PDlizszN MVTTRW5ITVJ?
OCI-AML2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;BbHZ3UUN3ME2wMlY2Ozl5IN88US=> MVXTRW5ITVJ?
RPMI-8226 NX;qZWZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3rTWM2OD1yLk[2N|I{KM7:TR?= MVjTRW5ITVJ?
MKN28 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwNk[2NlQh|ryP NYXxOlFyW0GQR1XS
MDA-MB-453 M13STGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HmTWlEPTB;MD62O|E5KM7:TR?= NWLiZZlbW0GQR1XS
BV-173 NVzUZ3FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwNki2O|kh|ryP NViwVWZIW0GQR1XS
NCI-H358 M3H2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXKdXVxUUN3ME2wMlY5PzJ4IN88US=> NVfMbmtYW0GQR1XS
NCI-H1651 NV\XPJNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTBwNzFOwG0> NUKxSVB2W0GQR1XS
MDA-MB-415 NFrkW41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vZfGlEPTB;MD63NFgzQSEQvF2= NWLV[Ih[W0GQR1XS
8305C MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILrUFNKSzVyPUCuO|I1QThizszN Mn\kV2FPT0WU
EFM-19 NXvJUGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnqPIdKSzVyPUCuO|M3PzFizszN NEjwSmRUSU6JRWK=
RERF-LC-MS NX2xXXR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwN{S2NVMh|ryP M4nU[HNCVkeHUh?=
A388 NGnaeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL5T3JKSzVyPUCuO|Y1PjdizszN M3;HO3NCVkeHUh?=
GI-ME-N MlW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvZVWV5UUN3ME2wMlc4OjN3IN88US=> NVjrVndEW0GQR1XS
IGR-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwN{mwOFMh|ryP NHzDeI9USU6JRWK=
LNCaP-Clone-FGC NGLxXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\MVWlEPTB;MD64NFAxPCEQvF2= NGSwbnBUSU6JRWK=
SK-MEL-3 NGnDO|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\tSJk6UUN3ME2wMlgyPTB6IN88US=> NX3QflViW0GQR1XS
UACC-257 NYGwOHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTXU4pKSzVyPUCuPFIzOzFizszN NGjlR5BUSU6JRWK=
OE33 NX:4TVllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYC0bHU{UUN3ME2wMlg2OTBzIN88US=> MXPTRW5ITVJ?
QIMR-WIL NEeyc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\wbmlEPTB;MD64OVE1OSEQvF2= NGD0O29USU6JRWK=
NCI-H2009 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DOTGlEPTB;MD64OVMyOSEQvF2= M2PYe3NCVkeHUh?=
NCI-H522 M1TsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PGc2lEPTB;MD64O|c5OyEQvF2= MoDtV2FPT0WU
Saos-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmriTWM2OD1yLki3PFcyKM7:TR?= NHrNfpVUSU6JRWK=
NB17 M4nrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfFfpF7UUN3ME2wMlg5ODJ3IN88US=> NFXUW3VUSU6JRWK=
D-392MG M1XuUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTOdINYUUN3ME2wMlg6OzV4IN88US=> NFPkW4ZUSU6JRWK=
SHP-77 NEfOfFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[0UWlEPTB;MD65NFQ5PSEQvF2= NH35U2ZUSU6JRWK=
SK-MEL-30 MkXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[wT2FKSzVyPUCuPVEyQDVizszN M{XjWXNCVkeHUh?=
GCIY M3;qdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KxTGlEPTB;MD65NVg1OyEQvF2= M16zNXNCVkeHUh?=
HCC70 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPQZ4ZKSzVyPUCuPVIxPTlizszN NGnvcnlUSU6JRWK=
LU-65 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjrRYlKSzVyPUCuPVI2QTFizszN Mn7xV2FPT0WU
NCI-H1563 M4HvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwOUS4OlUh|ryP M13jSXNCVkeHUh?=
KURAMOCHI NE\0VItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwOUWxPVIh|ryP M3O1XXNCVkeHUh?=
PA-1 M4TLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfV[Y1KSzVyPUCuPVU1OjRizszN MmDoV2FPT0WU
NOS-1 M121dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwOUe0PFkh|ryP M3\5dnNCVkeHUh?=
NCI-H69 MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEixT4NKSzVyPUCuPVc3OzRizszN MUjTRW5ITVJ?
KYSE-450 MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[4eYc1UUN3ME2wMlk5PjJ4IN88US=> MYTTRW5ITVJ?
8505C NVf4ZnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHP6fHNKSzVyPUCuPVk6QDJizszN NGS5PGtUSU6JRWK=
TGBC24TKB M1TqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DQbWlEPTB;MT6wNFA5PCEQvF2= M3PxV3NCVkeHUh?=
PFSK-1 NYixeIxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XjemlEPTB;MT6wNVQzQCEQvF2= M2XsTXNCVkeHUh?=
EKVX MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPkcINHUUN3ME2xMlA{OTJzIN88US=> NGnWSm5USU6JRWK=
RCM-1 NXrTW4t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmWxTWM2OD1zLkC1OVA4KM7:TR?= MlX2V2FPT0WU
SW900 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\TR4xVUUN3ME2xMlA4QDNizszN NHPrXHVUSU6JRWK=
D-542MG NEHtRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPiTWM2OD1zLkC3PFU2KM7:TR?= M17HOXNCVkeHUh?=
SK-PN-DW NWL2SZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfITWM2OD1zLkGwNFU3KM7:TR?= MkXvV2FPT0WU
NCI-H727 M3vSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4CwcmlEPTB;MT6xNFE2PCEQvF2= M4LM[nNCVkeHUh?=
SW837 NXjoeHl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofCTWM2OD1zLkGwPVU1KM7:TR?= NF\RN|BUSU6JRWK=
BT-20 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTYNoZEUUN3ME2xMlEyOjB2IN88US=> NV;JXJZMW0GQR1XS
RH-18 M4DGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzV[YpDUUN3ME2xMlE{OTB|IN88US=> M1TuZnNCVkeHUh?=
TE-12 NHHzTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPhTXhKSzVyPUGuNVM{OzNizszN MkSxV2FPT0WU
NB10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HWcmlEPTB;MT6xN|M1PCEQvF2= MWHTRW5ITVJ?
AU565 NVnNdVVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XIfWlEPTB;MT6xOVk4OyEQvF2= NXfVSZQyW0GQR1XS
OAW-42 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;6VGlEPTB;MT6xPFMxPiEQvF2= M{fmbHNCVkeHUh?=
DJM-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\2U2lEPTB;MT6xPVg5OSEQvF2= Mnr6V2FPT0WU
HH MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMkO4N|Eh|ryP MmrKV2FPT0WU
LAMA-84 M1ztRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DqOWlEPTB;MT6yO|M6PCEQvF2= MUXTRW5ITVJ?
KNS-42 NFjCfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwM{CyPVYh|ryP M{f1cHNCVkeHUh?=
NCI-H2052 NVXlRVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj3d297UUN3ME2xMlMxPTB5IN88US=> NVq0PJdbW0GQR1XS
MLMA NETDV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHw[I5KSzVyPUGuN|I1ODdizszN NV3qVHh{W0GQR1XS
NB12 MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTsTWM2OD1zLkO1OlM3KM7:TR?= NWfROZZ3W0GQR1XS
NCI-H1838 NWDPU245T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj1bodCUUN3ME2xMlM3OzB4IN88US=> MkCwV2FPT0WU
NCI-H526 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\a[ZJEUUN3ME2xMlM4QDV|IN88US=> NX6xe3I2W0GQR1XS
LS-123 NUnFZotPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnHclFKSzVyPUGuN|kxQTRizszN M3[2NHNCVkeHUh?=
HDLM-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3O[plKSzVyPUGuN|kzPzFizszN MnmyV2FPT0WU
MC-IXC NUXNdZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\yeoc4UUN3ME2xMlQzOzdzIN88US=> MVXTRW5ITVJ?
HCT-15 NFX4UodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\RXlBrUUN3ME2xMlQ{ODZ6IN88US=> MnLQV2FPT0WU
NCI-H596 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;qVWlEPTB;MT60OVA3OSEQvF2= NYj0eVNRW0GQR1XS
ZR-75-30 M1WzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwNEewPFIh|ryP M3TBd3NCVkeHUh?=
A704 NVrWWY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlf3TWM2OD1zLk[2OVY{KM7:TR?= NVjrbotJW0GQR1XS
OVCAR-4 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jJWWlEPTB;MT62PVYxPyEQvF2= NGXCWnFUSU6JRWK=
SW1417 NHzQXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rldWlEPTB;MT63Nlg1QSEQvF2= MnrBV2FPT0WU
CAS-1 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{mySWlEPTB;MT63N|k{PiEQvF2= Mk\tV2FPT0WU
IST-SL1 NV;SeXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLkOpJ7UUN3ME2xMlc6PzV7IN88US=> NIDRW5NUSU6JRWK=
A253 NIjGZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nU[2lEPTB;MT64NlI{QSEQvF2= M375[3NCVkeHUh?=
EW-16 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[1TWM2OD1zLkiyPFc2KM7:TR?= M2HJTXNCVkeHUh?=
SK-NEP-1 NV3XOJBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33FWmlEPTB;MT64Olk5QCEQvF2= NEnwNoxUSU6JRWK=
NCI-H226 NIDReoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvUfHZKSzVyPUGuPFk{PTlizszN MmDMV2FPT0WU
HOP-92 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LNbWlEPTB;MT65OlA6QSEQvF2= MYPTRW5ITVJ?
NCI-H441 NUD1dYlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof5TWM2OD1{LkCyN|M4KM7:TR?= MXTTRW5ITVJ?
LU-139 NHHlZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPxUYh1UUN3ME2yMlA{OTF2IN88US=> NGPTUmtUSU6JRWK=
SJRH30 M1HZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mli4TWM2OD1{LkC0NlU{KM7:TR?= MmTWV2FPT0WU
MG-63 NYW1NVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwMUSxNVEh|ryP NWTOU2VRW0GQR1XS
NH-12 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULibnFLUUN3ME2yMlE2ODB4IN88US=> NUnUb49GW0GQR1XS
NB7 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULIUFBOUUN3ME2yMlE6Pjd|IN88US=> MmWxV2FPT0WU
LB771-HNC M4LHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfjbopKSzVyPUKuNlA2QTVizszN M{\pb3NCVkeHUh?=
HCC1569 M3y5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzS[2s1UUN3ME2yMlI1PTh|IN88US=> MUTTRW5ITVJ?
D-283MED M{H1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDaU4tKSzVyPUKuNlQ4QDJizszN MUnTRW5ITVJ?
J-RT3-T3-5 NIG3dYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\oOVdjUUN3ME2yMlI2OzVzIN88US=> MlTaV2FPT0WU
ATN-1 NELJfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nOXmlEPTB;Mj6zN|A5OiEQvF2= NGHTbFFUSU6JRWK=
HCC1954 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzV[FZKSzVyPUKuN|Q1ODhizszN NFzvUFFUSU6JRWK=
SCC-15 NIH2coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLuZ3Z3UUN3ME2yMlM6OzF{IN88US=> NYn6[5RbW0GQR1XS
COLO-668 M1;BT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkL0TWM2OD1{LkSzNkDPxE1? NELNb21USU6JRWK=
LB373-MEL-D M1fIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmiyTWM2OD1{LkW0Olc4KM7:TR?= NVzLcmpxW0GQR1XS
no-10 M4fCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTQTWM2OD1{LkW0PVQ4KM7:TR?= MYjTRW5ITVJ?
HT-1197 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m3PGlEPTB;Mj62N|E5QCEQvF2= MmfsV2FPT0WU
DU-145 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;hS3ZKSzVyPUKuO|kyPjJizszN NUjmNZZkW0GQR1XS
SK-N-AS NGjle|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\JfXVrUUN3ME2yMlg1Pjl{IN88US=> M33lNXNCVkeHUh?=
MOLT-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rZUmlEPTB;Mj64OVMzOiEQvF2= MVXTRW5ITVJ?
EW-22 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHxcoJKSzVyPUKuPVI5PDFizszN M1z0PXNCVkeHUh?=
DB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq4UHRKSzVyPUKuPVc4PTlizszN NXW5VHNvW0GQR1XS
HL-60 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrvTWM2OD1|LkC0N|c3KM7:TR?= NGX1UGlUSU6JRWK=
SK-N-DZ NHHCZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTNwMEWwO|Uh|ryP MUTTRW5ITVJ?
NY M{\NPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVG2cVJ7UUN3ME2zMlA5PTR{IN88US=> MVnTRW5ITVJ?
T47D NXnwT416T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTUWIR6UUN3ME2zMlExPTV6IN88US=> MWTTRW5ITVJ?
NCI-H2029 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Qeo5KSzVyPUOuNlI1PzdizszN M{DWRXNCVkeHUh?=
KARPAS-299 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTNwMk[wNlch|ryP MXvTRW5ITVJ?
KM-H2 NUXEV28zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPGR2tZUUN3ME2zMlMxPjhizszN NIexOVFUSU6JRWK=
CHP-134 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOyRVVKSzVyPUOuOFc{QSEQvF2= M4fZfnNCVkeHUh?=
22RV1 NFvXSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvBTWM2OD1|LkS5NVY5KM7:TR?= M16zPXNCVkeHUh?=
NB5 NXLVV3ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTNwNUC2PFkh|ryP MoTOV2FPT0WU
CW-2 NFvw[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fiTGlEPTB;Mz61OVMyPCEQvF2= M3zIWXNCVkeHUh?=
EFO-21 Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwNU[5OEDPxE1? NWDF[5ZLW0GQR1XS
HuH-7 NXS0SYp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SxPGlEPTB;Mz61PFQyPCEQvF2= M1PwcnNCVkeHUh?=
ALL-PO NGfOR5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL2TWM2OD1|Lk[yN|M2KM7:TR?= NU\vPWIzW0GQR1XS
EM-2 M1n1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jMPWlEPTB;Mz62PVAyOSEQvF2= M4C1VXNCVkeHUh?=
KLE Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn70TWM2OD1|LkezNFI6KM7:TR?= M3m3bHNCVkeHUh?=
NEC8 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTNwOUG4NFgh|ryP MnjKV2FPT0WU
KP-N-YN M2izOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDqW2hKSzVyPUOuPVM1PzZizszN NIjmdmZUSU6JRWK=
SK-MEL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUO4[noyUUN3ME20MlA{PTF6IN88US=> NHzWV4FUSU6JRWK=
CAL-54 Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwMEW5NUDPxE1? NEL6b4tUSU6JRWK=
MS-1 NXT5SWdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHJTWM2OD12LkG2NVU2KM7:TR?= NYrLT3hkW0GQR1XS
NCI-H209 M2T5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fkd2lEPTB;ND6yPVk6QSEQvF2= NHjadWxUSU6JRWK=
NOMO-1 NY\QV|J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInhSZRKSzVyPUSuN|IyOzFizszN NX7QWmFsW0GQR1XS
RPMI-2650 NXzCUFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq3TWM2OD12LkO2N|I4KM7:TR?= M2fROnNCVkeHUh?=
NCI-H810 MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTRwM{m3N|Yh|ryP NWXLZ4I1W0GQR1XS
Ca9-22 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvmTWM2OD12LkS1OlkyKM7:TR?= NWq5e4pmW0GQR1XS
ES4 NYjw[|FFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTRwNEewPVUh|ryP MonTV2FPT0WU
ES6 NWT0ToJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvNNZdVUUN3ME20MlQ6PjV5IN88US=> M1LqOnNCVkeHUh?=
DMS-114 NF3vdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q1UWlEPTB;ND61OFY6OSEQvF2= NFnkW5ZUSU6JRWK=
ONS-76 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzxPHZYUUN3ME20MlU4QTVizszN NYLJ[I5PW0GQR1XS
K-562 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzY[ZhKSzVyPUSuO|M5OTRizszN NX7GSIQ1W0GQR1XS
MHH-NB-11 MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;PWGlEPTB;ND63OVQ3OSEQvF2= NF[wdVNUSU6JRWK=
Calu-3 NFrwTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fXNGlEPTB;ND63PFU1QCEQvF2= MnjPV2FPT0WU
HT55 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PVSGlEPTB;ND64OFU1PSEQvF2= MlzUV2FPT0WU
SK-N-FI Mn;3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTRwOEWwNFkh|ryP MY\TRW5ITVJ?
ES1 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnyOFFKSzVyPUSuPFYxPTdizszN M2LnT3NCVkeHUh?=
SF126 NFnOflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[xTJRUUUN3ME20Mlk{OTh2IN88US=> MXHTRW5ITVJ?
ES5 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml76TWM2OD13LkGyOFI4KM7:TR?= NHXOVW1USU6JRWK=
LoVo MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\hTWM2OD13LkG1PFcyKM7:TR?= M3;1TXNCVkeHUh?=
SNU-387 NGq3TIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K0XmlEPTB;NT6zNlM{QSEQvF2= MVHTRW5ITVJ?
C8166 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HXZWlEPTB;NT6zOlM{QSEQvF2= NYGzRpR6W0GQR1XS
LS-1034 MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojYTWM2OD13LkSyN|A4KM7:TR?= NInVVWFUSU6JRWK=
GR-ST MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TwWmlEPTB;NT61NlIxOSEQvF2= NEHF[mpUSU6JRWK=
NCI-H1092 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzYTWM2OD13LkeyPFQ{KM7:TR?= NWDGWVBWW0GQR1XS
647-V Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTYeowyUUN3ME21Mlc1PzB4IN88US=> NX35N2JoW0GQR1XS
EW-13 NX35THlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOydZZKSzVyPUWuO|Y3OjdizszN NEjUOmZUSU6JRWK=
KGN M{XLPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\PTWM2OD14LkC5PVIyKM7:TR?= NFX4UHpUSU6JRWK=
D-423MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXkN25KSzVyPU[uOFAzQDRizszN Ml3mV2FPT0WU
ECC10 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq4TZZMUUN3ME23MlExOTBzIN88US=> NWPVPXUxW0GQR1XS
TE-5 NU\1OGJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTdwNEGyPVgh|ryP NIjqelhUSU6JRWK=
P12-ICHIKAWA MlrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HKd2lEPTB;Nz60OVUzOyEQvF2= NYWyXYZPW0GQR1XS
NCI-H82 NXLNUo04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTdwNEW3NFEh|ryP NY\xSVRNW0GQR1XS
NCI-H1993 NUnxTJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13GN2lEPTB;Nz64N|A3OyEQvF2= NHOwPVBUSU6JRWK=
RH-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3YV3JKSzVyPUeuPFUzPDRizszN MVfTRW5ITVJ?
SW948 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjY[WVKSzVyPUeuPVYxPDlizszN MWXTRW5ITVJ?
CAL-33 NXq1XZVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvaTWM2OD15Lkm5PVM5KM7:TR?= NXjVNos1W0GQR1XS
U-266 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjUWIFKSzVyPUiuNVU4PzdizszN Ml\GV2FPT0WU
CAL-72 M2Lldmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn1OlFmUUN3ME24MlIxOzJizszN NVjJNVVlW0GQR1XS
SNU-423 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XvdGlEPTB;OT6zOlY3PiEQvF2= MUXTRW5ITVJ?
KG-1 NWO3eoI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvzfHZKSzVyPUmuOVg1PTZizszN Mnv1V2FPT0WU
HCC1395 NVPufFRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTlwOUKzOVIh|ryP NHu1TplUSU6JRWK=
BE-13 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHT[3FKSzVyPUGwMlg5QTJizszN NV;FZWNRW0GQR1XS
MKN7 NHj2TnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[xNGlEPTB;MUCuPVc3PSEQvF2= MUjTRW5ITVJ?
697 M2fabGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTCXmN1UUN3ME2xNU4yPDd{IN88US=> Mle5V2FPT0WU
LU-135 M1TLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMelI4UUN3ME2xNU4zOzB5IN88US=> MlrGV2FPT0WU
ES7 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkiyTWM2OD1zMT6zN|E{KM7:TR?= M1XhRnNCVkeHUh?=
SK-HEP-1 M1T5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFzLke2OFYh|ryP Mn3zV2FPT0WU
BEN MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\3dVdKSzVyPUGxMlg2OSEQvF2= MUHTRW5ITVJ?
NCI-H1770 NYjGWHA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLMTWM2OD1zMj6xNlYh|ryP M2nLW3NCVkeHUh?=
SW13 NUG5cnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjC[oxNUUN3ME2xNk4yPTRzIN88US=> NWPJ[YZrW0GQR1XS
MZ1-PC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvqTWM2OD1zMj61OFUzKM7:TR?= NEjhVWlUSU6JRWK=
Mo-T NGrNU4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF{Lke0NlEh|ryP MoLmV2FPT0WU
HLE NEK4cYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonHTWM2OD1zMj64NlE2KM7:TR?= MV\TRW5ITVJ?
RCC10RGB NV7acnVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nlZmlEPTB;MUOuOlcyKM7:TR?= NGO0blJUSU6JRWK=
COLO-320-HSR NWrIN4VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF|LkezPFEh|ryP NIXVOXhUSU6JRWK=
BHT-101 NGfxd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvNTWM2OD1zMz64N|Q2KM7:TR?= NXHGWoRSW0GQR1XS
OCUB-M Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF2LkG2NFIh|ryP M1:2N3NCVkeHUh?=
MEG-01 NX7jTWdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWf2eYdCUUN3ME2xOE4{PzB6IN88US=> M3v2fnNCVkeHUh?=
RS4-11 NEfIPXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXQbI5KSzVyPUG0Mlc1OiEQvF2= NHS4bGpUSU6JRWK=
MN-60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF2Lke4PVQh|ryP MXHTRW5ITVJ?
NCI-H1304 NXjvNWxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF3LkC0NlUh|ryP M4PuR3NCVkeHUh?=
Ramos-2G6-4C10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF3LkC1PFEh|ryP MoXFV2FPT0WU
NCI-H2342 NXLuN5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LhfWlEPTB;MUWuNlA1PCEQvF2= M4HheHNCVkeHUh?=
LAN-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF3LkS0NVQh|ryP M{TjbXNCVkeHUh?=
JVM-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF3LkW3OFgh|ryP MVnTRW5ITVJ?
P30-OHK NVnZOlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2H5cWlEPTB;MU[uNFYyPCEQvF2= MYHTRW5ITVJ?
C-33-A M1\Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq5T5BGUUN3ME2xOk43OjF2IN88US=> MYLTRW5ITVJ?
RPMI-8866 NUO3Rm9TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF4Lki0PVYh|ryP NVTlbJhzW0GQR1XS
NCI-H630 NXfRdolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF4Lki1N|ch|ryP M{Hkc3NCVkeHUh?=
KYSE-140 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF5LkKwNlgh|ryP NXXybohOW0GQR1XS
T84 NU\sdYRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF6Lki2PVUh|ryP M1O3WnNCVkeHUh?=
KU-19-19 NWTnVHNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\rTGlEPTB;MUiuPVYxQCEQvF2= NHTISHdUSU6JRWK=
BALL-1 NXHy[m5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7WUoJKSzVyPUG5MlM{QTlizszN NVrrTWJFW0GQR1XS
Calu-6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrMfIpKSzVyPUG5MlQ6OiEQvF2= M{PMW3NCVkeHUh?=
EGI-1 M{CzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTF7LkW5PEDPxE1? M{K3TnNCVkeHUh?=
MFH-ino MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\t[4JKSzVyPUG5Mlc1PTRizszN M3nBZnNCVkeHUh?=
GB-1 NWLGbHJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJyLkO1N|Uh|ryP MnLHV2FPT0WU
NCI-H1693 NVLQfo01T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fZemlEPTB;MkCuOlUxPSEQvF2= NUT0N4VuW0GQR1XS
SW1116 NILsN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJyLkmzOlIh|ryP MV;TRW5ITVJ?
H-EMC-SS MknKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF61dJlKSzVyPUKyMlA1PSEQvF2= M2DLWXNCVkeHUh?=
D-502MG M2DRNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr4TWM2OD1{Mj64NlYyKM7:TR?= NInRZohUSU6JRWK=
IA-LM MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLFc|VKSzVyPUKzMlI1QTNizszN MXTTRW5ITVJ?
SW1463 NIjkXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jIOmlEPTB;MkOuO|kh|ryP NVH2PFlPW0GQR1XS
JAR NEPBTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJ2LkOyPVMh|ryP Mm\kV2FPT0WU
HT MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn5fVZKSzVyPUK0MlQ4PTNizszN NIi3N3FUSU6JRWK=
LCLC-103H NYrTe2ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTJ2Lki0OFkh|ryP MXvTRW5ITVJ?
SNU-449 NHfqWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TVcGlEPTB;MkSuPFc1OSEQvF2= NWXx[VNoW0GQR1XS
KE-37 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTpU4dKSzVyPUK1MlA6OjhizszN MlrYV2FPT0WU
NCI-H1623 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jEN2lEPTB;MkeuNVMxOyEQvF2= M3LtSXNCVkeHUh?=
MOLT-13 NYm0N5lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2exNGlEPTB;MkeuN|UyPiEQvF2= NEHI[4dUSU6JRWK=
COLO-741 Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHxTWM2OD1|MT6zN|M{KM7:TR?= NYTsdJNuW0GQR1XS
NB6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN{LkK4O|Yh|ryP NGnaSndUSU6JRWK=
MOLT-16 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTNTWM2OD1|Mz6wNFU2KM7:TR?= MV7TRW5ITVJ?
IST-MES1 M4LxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e3XmlEPTB;M{SuNFU1OSEQvF2= MYnTRW5ITVJ?
A4-Fuk NVmwbWNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\qN5FWUUN3ME2zOU4xPjZizszN MoTqV2FPT0WU
CAL-85-1 NHTlPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTN3LkK4NVch|ryP MYfTRW5ITVJ?
CCRF-CEM M2i2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu1[pdKSzVyPUO3MlE2OzZizszN MkPJV2FPT0WU
HAL-01 NHzqXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7wTWM2OD1|OD60PFg6KM7:TR?= NXrYUZk4W0GQR1XS
HEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvITWM2OD12Mz6zOFA6KM7:TR?= NF;JUXRUSU6JRWK=
EW-1 M3fpbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSwXFhKSzVyPUSzMlQ4PjhizszN NHfSO2RUSU6JRWK=
MDA-MB-231 NXfI[FNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2j3SWlEPTB;NEWuNVE6QSEQvF2= M{\sb3NCVkeHUh?=
ABC-1 NUXUd45PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\lS2NKSzVyPUS2Mlg2OzhizszN MoTmV2FPT0WU
NCI-H446 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTR6LkWwOVgh|ryP NUn1Z2RkW0GQR1XS
MHH-PREB-1 NFnTXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTR7Lk[wNFch|ryP MlX3V2FPT0WU
DOHH-2 NHe0N4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DhOWlEPTB;NEmuOlY2PiEQvF2= NVXuWpZFW0GQR1XS
GCT NU\2WXByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LiZ2lEPTB;NEmuOlk4PiEQvF2= MVfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo 17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. [1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. [2]

Protocol

Kinase Assay
+ Expand

Hsp90 binding assays:

Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl2, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research
+ Expand
  • Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 5 days
  • Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A490) of wells not containing cells is subtracted. Percentage of viable cells = (A490 of 17-AAG treated sample/A490 untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6
  • Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle
  • Dosages: ~50 mg/kg
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (170.73 mM)
Ethanol 5 mg/mL (8.53 mM)
Water <1 mg/mL
In vivo 5%DMSO+corn oil 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 585.69
Formula

C31H43N3O8

CAS No. 75747-14-7
Storage powder
in solvent
Synonyms CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00577889 Completed Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage IV Pancreatic Cancer National Cancer Institute (NCI) March 2008 Phase 2
NCT00546780 Completed Multiple Myeloma Bristol-Myers Squibb February 2008 Phase 3
NCT00093496 Completed Primary Peritoneal Cavity Cancer|Recurrent Ovarian Epithelial Cancer|Stage III Ovarian Epithelial Cancer|Stage IV Ovarian Epithelial Cancer National Cancer Institute (NCI) October 2007 Phase 2
NCT00514371 Completed Multiple Myeloma Bristol-Myers Squibb August 2007 Phase 2|Phase 3
NCT00779428 Completed Advanced Malignancies Bristol-Myers Squibb July 2006 Phase 2
NCT00354185 Terminated Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Adult T-cell Leukemia/Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Adult T-cell Leukemia/Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific|Waldenström Macroglobulinemia National Cancer Institute (NCI) May 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?

  • Answer:

    17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Tags: buy 17-AAG (Tanespimycin) | 17-AAG (Tanespimycin) supplier | purchase 17-AAG (Tanespimycin) | 17-AAG (Tanespimycin) cost | 17-AAG (Tanespimycin) manufacturer | order 17-AAG (Tanespimycin) | 17-AAG (Tanespimycin) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID